Annovis Bio announces trial design of their planned Phase 3 trial evaluating buntanetap (posiphen) in early #Parkinsons; 450 PD participants H&Y 1-3, randomized 1:1:1 (placebo, 10mg or 20mg once daily); MDS-UPDRS II & III as primary endpoints
Annovis Bio announces trial design of the... - Cure Parkinson's
Annovis Bio announces trial design of their planned Phase 3 trial evaluating buntanetap (posiphen) in early Parkinsons
3 Replies
•
Another good one
No locations posted here yet. clinicaltrials.gov/ct2/show...
Not what you're looking for?
You may also like...
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?airportNewsID=e4e0b40
Annovis Bio's Phase 3 trial of Buntanetap/Posiphen: Trial record has been updated (contacts and locations)
There are now 18 locations mentioned in the updated trial record (September 12, 2022):
- one in...
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s...
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
This trial is already open in the United States, and I believe some on this forum are...
Anyone participating in the Buntanetap Phase 3 trial?
Would love to hear your initial feedback. I'm considering participating. Full info here:...
Related Posts
ANNOVIS BIO ANNOUNCES POSITIVE FDA FEEDBACK FOR BUNTANETAP PHASE 3 CLINICAL DEVELOPMENT IN PARKINSON'S DISEASE (ANVS401)
Annovis Phase 3 Trial - has anyone participated?
Anxious to hear any updates from Annovis Bio Butanetap phase 3 trial cohorts
Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
